Rheumatic Disease
Virtual Grand Rounds
Treatment of the Patient With
Early Rheumatoid Arthritis
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: November 10, 2011
Expiration Date: November 10, 2012
Estimated Time of Completion: 45 minutes
Description
The purpose of this activity is to discuss treatment strategies for patients with early RA.
Learning Objectives
- Identify a strategy to make or confirm an early diagnosis of RA.
- Explain how RA disease activity measures can guide treatment decisions.
- Describe features of a treat-to-target treatment algorithm.
Target Audience
This activity is intended for rheumatologists, primary care physicians, and other clinicians who treat patients with rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout, systemic lupus erythematosus (SLE), and antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
RJ Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
Faculty
Allan Gibofsky, MD, JD, FACP, FCLM
Professor of Medicine and Public Health
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, New York
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Leonard Calabrese, DO |
||
| Amgen Inc.: |
Consulting, Teaching and Speaking | |
| Bristol-Myers Squibb Company: | Consulting, Teaching and Speaking | |
| Centocor, Inc.: | Consulting, Teaching and Speaking | |
| Pfizer Inc.: | Consulting, Teaching and Speaking | |
| Roche-Genentech: | Consulting, Teaching and Speaking | |
The following faculty member has indicated that he has no relationships which, in the context of his presentation, could be perceived as potential conflicts of interest:
Allan Gibofsky, MD, JD, FACP, FCLM
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:
Abbott Laboratories
Genentech, Inc.
This CME activity was produced by the
Cleveland Clinic Foundation
Center for Continuing Education and
